126 related articles for article (PubMed ID: 10984261)
21. Effect of 6 months of growth hormone treatment in young children with Prader-Willi syndrome.
Eiholzer U; Weber R; Stutz K; Steinert H
Acta Paediatr Suppl; 1997 Nov; 423():66-8. PubMed ID: 9401543
[TBL] [Abstract][Full Text] [Related]
22. The behavioral impact of growth hormone treatment for children and adolescents with Prader-Willi syndrome: a 2-year, controlled study.
Whitman BY; Myers S; Carrel A; Allen D
Pediatrics; 2002 Feb; 109(2):E35. PubMed ID: 11826245
[TBL] [Abstract][Full Text] [Related]
23. Diagnosis and treatment of GH deficiency in Prader-Willi syndrome.
Grugni G; Marzullo P
Best Pract Res Clin Endocrinol Metab; 2016 Dec; 30(6):785-794. PubMed ID: 27974191
[TBL] [Abstract][Full Text] [Related]
24. Response to growth hormone treatment in Prader-Willi syndrome: auxological criteria versus genetic diagnosis.
Scheermeyer E; Hughes I; Harris M; Ambler G; Crock P; Verge CF; Craig ME; Bergman P; Werther G; van Driel M; Davies PS; Choong CS
J Paediatr Child Health; 2013 Dec; 49(12):1045-51. PubMed ID: 23781979
[TBL] [Abstract][Full Text] [Related]
25. Body composition studies in Prader-Willi syndrome: effects of growth hormone therapy.
Lee PD; Hwu K; Henson H; Brown BT; Bricker JT; LeBlanc AD; Fiorotto ML; Greenberg F; Klish WJ
Basic Life Sci; 1993; 60():201-5. PubMed ID: 8110110
[No Abstract] [Full Text] [Related]
26. Effects of growth hormone in Prader-Willi syndrome. A case report.
Ruvalcaba RH; Holm VA
Clin Pediatr (Phila); 1993 May; 32(5):292-5. PubMed ID: 8324972
[No Abstract] [Full Text] [Related]
27. Benefits of long-term GH therapy in Prader-Willi syndrome: a 4-year study.
Carrel AL; Myers SE; Whitman BY; Allen DB
J Clin Endocrinol Metab; 2002 Apr; 87(4):1581-5. PubMed ID: 11932286
[TBL] [Abstract][Full Text] [Related]
28. Growth hormone therapy and scoliosis in patients with Prader-Willi syndrome.
Nagai T; Obata K; Ogata T; Murakami N; Katada Y; Yoshino A; Sakazume S; Tomita Y; Sakuta R; Niikawa N
Am J Med Genet A; 2006 Aug; 140(15):1623-7. PubMed ID: 16770808
[TBL] [Abstract][Full Text] [Related]
29. Early manifestations of Prader-Willi syndrome: influence of growth hormone.
Eiholzer U; Schlumpf M; Nordmann Y; l'Allemand D
J Pediatr Endocrinol Metab; 2001; 14 Suppl 6():1441-4. PubMed ID: 11837497
[TBL] [Abstract][Full Text] [Related]
30. Physical effects of growth hormone treatment in children with Prader-Willi syndrome.
Myers SE; Carrel AL; Whitman BY; Allen DB
Acta Paediatr Suppl; 1999 Dec; 88(433):112-4. PubMed ID: 10626559
[TBL] [Abstract][Full Text] [Related]
31. What is the value of growth hormone therapy in Prader Willi syndrome?
Bridges N
Arch Dis Child; 2014 Feb; 99(2):166-70. PubMed ID: 24162007
[TBL] [Abstract][Full Text] [Related]
32. Adult patients with Prader-Willi syndrome: clinical characteristics, life circumstances and growth hormone secretion.
Partsch CJ; Lämmer C; Gillessen-Kaesbach G; Pankau R
Growth Horm IGF Res; 2000 Apr; 10 Suppl B():S81-5. PubMed ID: 10984259
[TBL] [Abstract][Full Text] [Related]
33. Carbohydrate metabolism is not impaired after 3 years of growth hormone therapy in children with Prader-Willi syndrome.
L'Allemand D; Eiholzer U; Schlumpf M; Torresani T; Girard J
Horm Res; 2003; 59(5):239-48. PubMed ID: 12714788
[TBL] [Abstract][Full Text] [Related]
34. Current indications for growth hormone therapy for children and adolescents.
Richmond E; Rogol AD
Endocr Dev; 2010; 18():92-108. PubMed ID: 20523020
[TBL] [Abstract][Full Text] [Related]
35. Sustained benefits of growth hormone on body composition, fat utilization, physical strength and agility, and growth in Prader-Willi syndrome are dose-dependent.
Carrel AL; Myers SE; Whitman BY; Allen DB
J Pediatr Endocrinol Metab; 2001; 14(8):1097-105. PubMed ID: 11592566
[TBL] [Abstract][Full Text] [Related]
36. Growth hormone (GH) response to combined pyridostigmine and GH-releasing hormone administration in patients with Prader-Labhard-Willi syndrome.
Cappa M; Grossi A; Borrelli P; Ghigo E; Bellone J; Benedetti S; Carta D; Loche S
Horm Res; 1993; 39(1-2):51-5. PubMed ID: 8406340
[TBL] [Abstract][Full Text] [Related]
37. Growth hormone treatment and adverse events in Prader-Willi syndrome: data from KIGS (the Pfizer International Growth Database).
Craig ME; Cowell CT; Larsson P; Zipf WB; Reiter EO; Albertsson Wikland K; Ranke MB; Price DA;
Clin Endocrinol (Oxf); 2006 Aug; 65(2):178-85. PubMed ID: 16886957
[TBL] [Abstract][Full Text] [Related]
38. Is scoliosis an issue for giving growth hormone to children with Prader-Willi syndrome?
Diene G; de Gauzy JS; Tauber M
Arch Dis Child; 2008 Dec; 93(12):1004-6. PubMed ID: 19028967
[No Abstract] [Full Text] [Related]
39. Low dose growth hormone treatment in infants and toddlers with Prader-Willi syndrome is comparable to higher dosage regimens.
Scheermeyer E; Harris M; Hughes I; Crock PA; Ambler G; Verge CF; Bergman P; Werther G; Craig ME; Choong CS; Davies PSW;
Growth Horm IGF Res; 2017 Jun; 34():1-7. PubMed ID: 28427039
[TBL] [Abstract][Full Text] [Related]
40. Analysis of NREM sleep in children with Prader-Willi syndrome and the effect of growth hormone treatment.
Verrillo E; Bruni O; Franco P; Ferri R; Thiriez G; Pavone M; Petrone A; Paglietti MG; Crinò A; Cutrera R
Sleep Med; 2009 Jun; 10(6):646-50. PubMed ID: 19027358
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
